Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**T-complex protein 1 subunit gamma (CCT3)** is a molecular chaperone and a core component of the TRiC/CCT chaperonin complex, which consists of two stacked rings with eight distinct subunits each[1][3][4]. CCT3 assists in the correct folding of a diverse range of client proteins, notably actin and tubulin, via an ATP-dependent mechanism, thereby ensuring protein homeostasis and regulating key cellular functions such as mitosis, apoptosis, and signal transduction[1][2][3][4]. CCT3 and the TRiC/CCT complex play important roles in cell cycle progression and the maintenance of cytoskeletal integrity. CCT3 is frequently upregulated in various cancers, where it facilitates oncogenic signaling (e.g., STAT3 pathway) and serves as a prognostic marker and potential therapeutic target[1][2]. Beyond cancer, CCT3 has roles in neurodevelopment and neurodegeneration, further emphasizing its importance in cellular proteostasis[2][3]. No direct drugs targeting CCT3 are currently listed, but its central role in oncogenic pathways and as a biomarker highlights its potential for future therapeutic targeting[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-complex protein 1 subunit gamma (CCT3).